Thus, paradoxical as it may seem, the inadvertent upregulation of PD‐L1 by pharmaceuticals could be beneficial in conversion of a traditionally insensitive cancer to one that is immunotherapeutically targetable. The gene discussed is CD274; the disease is cancer.